Last week, readers were most interested in a story about Diasorin's preparation to enter the point-of-care molecular testing space with a benchtop instrument.

China's volume-based procurement policy and US tariffs have forced companies with large businesses in China to reset their ...

Stakeholders suggested that while the FDA rule is dead, updates to LDT regulation are coming, nonetheless, and the industry ...

Some experts believe a technological tipping point is imminent, if not already here, but adoption of point-of-care MDx has ...

The target device includes a portable instrument and 30-minute, $5 assays requiring only small volumes of whole capillary blood.

The development marks a shift up the value chain for labs and could prove a meaningful revenue stream for providers able to ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus ...

The South Korean firm said that its CURECA system offers walkaway PCR testing with 24/7 operation without human intervention ...

The firm's genomics revenues more than doubled year over year, while data and services revenue increased nearly 36 percent.

The firm is aiming to accelerate growth in its molecular business by expanding menu and driving adoption of additional testing.

The test is compatible with lateral flow technology and could be used to provide tuberculosis testing in low-resource settings.